File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Decline in hepatitis B surface antigen levels with entecavir treatment in HBeAg-positive nucleoside naive chronic hepatitis B patients-results from phase III study ETV-022

TitleDecline in hepatitis B surface antigen levels with entecavir treatment in HBeAg-positive nucleoside naive chronic hepatitis B patients-results from phase III study ETV-022
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2012
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
Digestive Disease Week (DDW), San Diego, CA, USA between 19-22 May 2012. In Gastroenterology, 2012, v. 142 n. 5, suppl. 1, p. S-917, abstract no. 469 How to Cite?
AbstractBACKGROUND: Entecavir (ETV) 0.5 mg demonstrated superior virologic, histologic, and biochemical benefit compared to lamivudine in phase III study ETV-022. Through 96 weeks of treatment and 24 weeks post-treatment follow-up, 5% of the patients achieved HBsAg loss. We present the changes in quantitative HBsAg levels in patients with HBeAg-positive nucleoside naive chronic hepatitis B patients treated with ETV in study ETV-022. METHODS: The nucleoside-naive HBeAg-positive patients received ETV 0.5mg daily in study ETV-022. HBsAg levels were assessed qualitatively and quantitatively every 12 weeks. The quantitative HBsAg levels were measured with the Abbott Architect Assay. Mean HBsAg levels were calculated at baseline, week 12, 24, 36 and 48 for the overall cohort and cohorts with HBeAg loss or HBsAg loss. RESULTS: A total of 95 ETV-treated patients from study ETV-022 had available blood samples and were analyzed for quantitative HBsAg levels. Baseline characteristics of patients include mean age 38 years old, mean HBV DNA 9.64 log10 copies/mL and ALT 156.65 U/L. The quantitative HBsAg levels over time in different patient groups are shown below. CONCLUSION: Quantitative HBsAg levels decreased overtime during the first 48 weeks of ETV therapy in HBeAg-positive nucleoside naive patients. A greater decline in quantitative HBsAg value was observed among subjects who had HBeAg loss or HBsAg loss.
DescriptionThis journal suppl. entitled: 2012 DDW Abstract Supplement to Gastroenterology
Persistent Identifierhttp://hdl.handle.net/10722/165461
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170

 

DC FieldValueLanguage
dc.contributor.authorGish, Ren_US
dc.contributor.authorChang, TTen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorDe Man, RAen_US
dc.contributor.authorGadano, Aen_US
dc.contributor.authorYu, Sen_US
dc.contributor.authorLlamoso, Cen_US
dc.contributor.authorTang, Hen_US
dc.date.accessioned2012-09-20T08:18:24Z-
dc.date.available2012-09-20T08:18:24Z-
dc.date.issued2012en_US
dc.identifier.citationDigestive Disease Week (DDW), San Diego, CA, USA between 19-22 May 2012. In Gastroenterology, 2012, v. 142 n. 5, suppl. 1, p. S-917, abstract no. 469en_US
dc.identifier.issn0016-5085-
dc.identifier.urihttp://hdl.handle.net/10722/165461-
dc.descriptionThis journal suppl. entitled: 2012 DDW Abstract Supplement to Gastroenterology-
dc.description.abstractBACKGROUND: Entecavir (ETV) 0.5 mg demonstrated superior virologic, histologic, and biochemical benefit compared to lamivudine in phase III study ETV-022. Through 96 weeks of treatment and 24 weeks post-treatment follow-up, 5% of the patients achieved HBsAg loss. We present the changes in quantitative HBsAg levels in patients with HBeAg-positive nucleoside naive chronic hepatitis B patients treated with ETV in study ETV-022. METHODS: The nucleoside-naive HBeAg-positive patients received ETV 0.5mg daily in study ETV-022. HBsAg levels were assessed qualitatively and quantitatively every 12 weeks. The quantitative HBsAg levels were measured with the Abbott Architect Assay. Mean HBsAg levels were calculated at baseline, week 12, 24, 36 and 48 for the overall cohort and cohorts with HBeAg loss or HBsAg loss. RESULTS: A total of 95 ETV-treated patients from study ETV-022 had available blood samples and were analyzed for quantitative HBsAg levels. Baseline characteristics of patients include mean age 38 years old, mean HBV DNA 9.64 log10 copies/mL and ALT 156.65 U/L. The quantitative HBsAg levels over time in different patient groups are shown below. CONCLUSION: Quantitative HBsAg levels decreased overtime during the first 48 weeks of ETV therapy in HBeAg-positive nucleoside naive patients. A greater decline in quantitative HBsAg value was observed among subjects who had HBeAg loss or HBsAg loss.-
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro-
dc.relation.ispartofGastroenterologyen_US
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleDecline in hepatitis B surface antigen levels with entecavir treatment in HBeAg-positive nucleoside naive chronic hepatitis B patients-results from phase III study ETV-022en_US
dc.typeConference_Paperen_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.doi10.1016/S0016-5085(12)63560-4-
dc.identifier.hkuros211059en_US
dc.identifier.volume142en_US
dc.identifier.issue5, suppl. 1en_US
dc.identifier.spageS-917en_US
dc.identifier.epageS-917en_US
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats